I know it has been the plan to partner however it has never been the only way forward. For CLBP we have the funds.
I also question the popular belive that a partner somehow makes the application easy to get past the FDA.
Then if we were to partner , say CLBP would we not in effect be selling a substantial part of that indication , we would also be selling our backup to a faillure in other indications. I would probably not be here without a substantial back up. I do not want to be a invester in a one drug companie.
Remestemcel on the other hand. Lets just let the FDA do its job and approve the therapy for GVHD. We can then look at a development plan.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-46
-
- There are more pages in this discussion • 162 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |